Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 8/20 | 0.67 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.67 |
| ▸ | TNNC1 | P63316 | 6/20 | 0.67 |
| ▸ | S1PR4 | O95977 | 6/20 | 0.67 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.67 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.67 |
| ▸ | GPR183 | P32249 | 1/20 | 0.67 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.67 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.54 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.54 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.51 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6260040 | 0.98 | S1PR1 (0.68) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| SCHEMBL20814029 | 0.86 | LIPG (0.50) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| SCHEMBL16800252 | 0.82 | LIPG (0.53) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| SCHEMBL20813856 | 0.81 | LIPG (0.51) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| SCHEMBL29272511 | 0.81 | LIPG (0.59) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| SCHEMBL18904548 | 0.80 | S1PR1 (1.00) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| SCHEMBL3390328 | 0.80 | S1PR1 (1.00) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| SCHEMBL3392313 | 0.80 | S1PR1 (1.00) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| Fingolimod SCHEMBL7445 | 0.80 | S1PR1 (1.00) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| SCHEMBL3393539 | 0.80 | S1PR1 (1.00) | S1PR1S1PR3TNNC1S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518733-B2 | Process for preparation of highly pure Fingolimod hydrochloride | SHIVALIK RASAYAN LIMITED (IN) | 2022-12-06 | — | — | US | disclosed |
| EP-3074374-B1 | FINGOLIMOD HYDROCHLORIDE PROCESS | EMCURE PHARMACEUTICALS LTD (IN) | 2019-03-13 | — | — | EP | disclosed |
| EP-2807143-B1 | PROCESS FOR PREPARATION OF FINGOLIMOD | GLENMARK GENERICS LTD (IN) | 2017-08-30 | — | — | EP | disclosed |
| EP-3193870-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES WITH COMBINATION OF LAQUINIMOD AND FINGOLIMOD | Teva Pharmaceutical Industries Ltd. (IL) | 2017-07-26 | — | — | EP | disclosed |
| US-9643914-B2 | Fingolimod hydrochloride process | EMCURE PHARMACEUTICALS LIMITED (IN) | 2017-05-09 | — | — | US | disclosed |
| US-9643914-B2 | Fingolimod hydrochloride process | EMCURE PHARMACEUTICALS LIMITED (IN) | 2017-05-09 | — | — | US | disclosed |
| US-20160289166-A1 | FINGOLIMOD HYDROCHLORIDE PROCESS | EMCURE PHARMACEUTICALS LIMITED (IN) | 2016-10-06 | — | — | US | disclosed |
| US-20160289166-A1 | FINGOLIMOD HYDROCHLORIDE PROCESS | EMCURE PHARMACEUTICALS LIMITED (IN) | 2016-10-06 | — | — | US | disclosed |
| WO-2016044103-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES WITH COMBINATION OF LAQUINIMOD AND FINGOLIMOD | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2016-03-24 | — | — | WO | disclosed |
| WO-2015092809-A2 | FINGOLIMOD HYDROCHLORIDE PROCESS | EMCURE PHARMACEUTICALS LIMITED (IN) | 2015-06-25 | — | — | WO | disclosed |
| US-9056813-B2 | Process for preparation of fingolimod | GLENMARK GENERICS LIMITED (IN) | 2015-06-16 | — | — | US | disclosed |
| WO-2013111162-A2 | PROCESS FOR PREPARATION OF FINGOLIMOD | GLENMARK GENERICS LIMITED (IN) | 2013-08-01 | — | — | WO | disclosed |
| US-5952316-A | FOR TREATING AUTOIMMUNE DISEASES, E.G., RHEUMATIOD ARTHRITIS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-14 | — | — | US | disclosed |
| EP-0627406-B1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL (JP) | 1998-10-28 | — | — | EP | disclosed |
| US-5719176-A | 2-amino-1,3-propanediol compound and immunosuppressant | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-02-17 | — | — | US | disclosed |
| US-5604229-A | 2-amino-1,3-propanediol compound and immunosuppressant | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-02-18 | — | — | US | disclosed |
| EP-0627406-A1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518733-B2 | Process for preparation of highly pure Fingolimod hydrochloride | S1PR5, S1PR4, S1PR1 | S1PR1 3/4885S1PR3 4/4885TNNC1 4286/4885 |
| US-20160289166-A1 | FINGOLIMOD HYDROCHLORIDE PROCESS | S1PR4, S1PR2, S1PR3 | S1PR1 4/4885S1PR3 3/4885TNNC1 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.